Skip to main content

Day: June 8, 2020

Formula Systems Acquires 70% of Liram Financial Software Ltd.

The acquisition, completed by Michpal Micro Computers, a wholly owned subsidiary of Formula Systems, enables Michpal to expand its operations in the field Financial Accounting, Taxation and Compliance for accounting firms, tax consultants, bookkeepers, controllers, and CFOs.Or Yehuda, Israel, June 08, 2020 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (NASDAQ and TASE: FORTY) announced today that it had completed the acquisition of 70% of the share capital of Liram Finance Software Ltd. (“Liram”).Liram is a provider of proprietary integrated specialized management systems in the field of financial accounting, taxation and compliance, for accounting professionals (accountants and tax consultants), bookkeepers, controllers, and CFOs, giving its clients, for more than 35 years, complete confidence in their actions and decisions. Liram’s...

Continue reading

DynaEnergetics Introduces DS Echo™ Perforating System for Re-frac Applications in Unconventional Wells

HOUSTON, June 08, 2020 (GLOBE NEWSWIRE) — DynaEnergetics, a business of DMC Global Inc. (Nasdaq: BOOM), today introduced DS Echo, a perforating system designed for re-frac operations in unconventional oil and gas wells.  The system’s slim design enables deployment within the smaller-diameter secondary casing of a previously completed well. DS Echo is equipped with EchoFrac™ shaped charges, which were developed specifically for re-frac applications. EchoFrac charges deliver uniform entry-hole diameter and enough perforating punch to penetrate two layers of casing, regardless of gun positioning. The result is better fracture treatments, and ultimately, better production volumes.  EchoFrac’s clean perforations of both casings ensure the integrity of the cement sheath between the inner and the outer strings, as well as the cement-to-formation...

Continue reading

CytoDyn Receives BLA Acknowledgment Letter From the FDA

PDUFA date could be set by the FDA on July 10VANCOUVER, Washington, June 08, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the U.S. Food and Drug Administration (FDA) advised the Company, subject to its ongoing review, it could receive its “PDUFA date” on July 10, 2020.  Under the Prescription Drug User Fee Act (PDUFA), the FDA sets a goal date for the agency to complete its review of a new drug application; this date is commonly referred to as the “PDUFA date.” The FDA’s standard review time for new drug applications is 10 months.  The Company’s drug candidate, leronlimab, was previously granted Fast Track designation by the FDA...

Continue reading

KRONOS ADVANCED TECHNOLOGIES INC (TICKER: KNOS) ANNOUNCES HIRING PCAOB QUALIFIED CPA FIRM TO AUDIT TWO YEARS OF THE COMPANY’S FINANCIAL STATEMENTS;

Los Angeles, CA, June 08, 2020 (GLOBE NEWSWIRE) — Los Angeles, CA, June 8, 2020 (GLOBENEWSWIRE) KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) (“KNOS” or the “Company”), a product development and production company that has significantly changed the way air is moved, filtered, and sterilized today announced that it engaged a PCAOB qualified CPA to audit the past two years of the Company’s financials. “We believe hiring a PCAOB auditor for our Company is a significant move that demonstrates our commitment to shareholders and customers,” said Michael Rubinov, Kronos President. “Preparing for the PCAOB audit will allow us to start the process to move from the OTC markets to achieve a listed company status over the next 3 to 5 quarters.” We decided to begin the work needed...

Continue reading

Kezar Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock in the offering will be sold by Kezar. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.Jefferies, Cowen and William Blair are acting as joint book-running managers for the offering. Kezar expects to grant the underwriters a 30-day option to purchase additional shares of common stock in the proposed offering of...

Continue reading

Can B Corp Advances Toward Full Vertical Integration with Hemp Processing Agreement

HICKSVILLE, NY, June 08, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a diversified health and wellness company, is pleased to announce the signing of the Hemp Processing Use Agreement (“Agreement”) executed on May 28, 2020, between Green Grow Farms, Inc. (“Green Grow Farms”), a wholly-owned subsidiary of Can B, and Mediiusa Group, Inc. (“Mediiusa”).“With the signing of this agreement, I am pleased to report Can B, through our Green Grow Farms division, will achieve full vertical integration,” said Marco Alfonsi, CEO.Alfonsi continued, “Can B presently grows its own hemp through its Green Grow Farms Division and now, we can process that hemp under our exclusive agreement with Mediiusa’s utilizing their Hemp Processing Registration with the State of New York. That hemp biomass can...

Continue reading

Ferratum Oyj – Managers’ Transactions – Liigus

Ferratum Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: LL Capital Investments OÜPosition: Closely associated person(X) Legal person(1):Person Discharging Managerial Responsibilities In IssuerName: Liigus, LeaPosition: Member of the BoardIssuer: Ferratum OyjLEI: 74370078YLPFWHE33716Notification type: INITIAL NOTIFICATIONReference number: 74370078YLPFWHE33716_20200608104036_6____________________________________________Transaction date: 2020-06-04Venue: XETRA – REGULIERTER MARKT (XETA)Instrument type: SHAREISIN: FI4000106299Nature of the transaction: ACQUISITIONTransaction details(1): Volume: 5,000 Unit price: 5 EURAggregated transactions(1): Volume: 5,000 Volume weighted average price: 5 EUR

Continue reading

Plc Uutechnic Group Oyj: CORRECTION TO THE PLC UUTECHNIC GROUP OYJ’S INVITATION TO THE ANNUAL GENERAL MEETING

PLC UUTECHNIC GROUP OYJ STOCK EXCHANGE RELEASE 8 June 2020 at 12:50 pmCORRECTION TO THE PLC UUTECHNIC GROUP OYJ’S INVITATION TO THE ANNUAL GENERAL MEETINGThis is a correction to Plc Uutechnic Group Oyj’s invitation to the Annual General Meeting published on June 8, 2020 at 10:00 am. The date of the Annual General Meeting was incomplete in the English translation. Correction: The Annual General Meeting will be held on Tuesday June 30, 2020, starting at 13.00.Below the invitation in its entirety:INVITATION TO THE ANNUAL GENERAL MEETING OF PLC UUTECHNIC GROUP OYJPlc Uutechnic Group Oyj shareholders are hereby invited to the Annual General Meeting that will be held on Tuesday June 30, 2020, starting at 13.00 at Voimala Zaku, Suukarintie 6 B, 23500 UusikaupunkiThe aim is to hold the Annual General Meeting as short as possible No catering or...

Continue reading

RESULT OF SEK CREDIT OPERATION 2020-06-08

June 08, 2020 05:45 ET | Source: Sveriges RiksbankRESULT OF SEK CREDIT OPERATION 2020-06-08  Auction date: 2020-06-08Payment date: 2020-06-08 (at 3 pm)Maturity date: 2020-09-08Term: 92 daysOffered volume: UnlimitedTotal bid amount: SEK 0 billionNumber of bids 0Allotment: SEK 0 billionInterest rate: Repo rate + 0,20 percentage pointsProfileSveriges RiksbankStockholm, SWEDENMedia FilesFormats available:

Continue reading

Cataract Surgical Devices Market to Rise at 5.4% CAGR till 2026 Driven by Recent Technological Advancements, says Fortune Business Insights™

Pune, June 08, 2020 (GLOBE NEWSWIRE) — The global cataract surgical devices market size is projected to reach USD 9.98 billion by the end of 2026. The high prevalence of cataract disorders will open up a huge potential for market growth. According to a report published by Fortune Business Insights, titled “Cataract Surgical Devices Market Size, Share & Industry Analysis, By Product Type (Phacoemulsification Systems, Femtosecond Laser, Intraocular Lenses, Ophthalmic Viscoelastic Devices & Other Consumables), By End-user (Hospitals, Ophthalmic Clinics, Others), and Regional Forecast, 2019-2026,” the market was worth USD 6.56 billion in 2018 and will exhibit a CAGR of 5.4% during the forecast period, 2019-2026.In addition to this, the favourable health reimbursement policies have contributed to the growing adoption of cataract...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.